Clinical Significance of Multi-Cancer Genome Profiling: Data from A Japan Hospital

Abstract

Aim New hopes for “precision cancer care” hinge on the success of individualized cancer genome profiling at predicting the therapeutic efficacy of various anticancer drug treatments in eligible patients. We aimed to clarify the significance of cancer genome profiling in Japan by analyzing the clinical data from cancer genome testing of various solid cancers at our hospital. Materials and Methods A total of 230 patients examined by one of three tests for multi-cancer genome profiling including NCC Oncopanel, FoundationOne CDx, and FoundationOne Liquid were retrospectively enrolled. Adequate treatment for each patient was discussed at the expert panel meeting according to the results from the genome profiling tests. Results The most frequent cancer types enrolled in this study were pancreas cancer, bowel cancer, and biliary cancer. Druggable cases comprised 108 (47%) of 230 cases, and 21 (9.1%) of 230 cases actually received medication. Partial Response (PR) was found in 7 (33%) of the 21 cases Three cases of biliary cancer and three cases of BRCA2 mutation were included among the seven PR cases. Conclusion Twenty-one (9.1%) of 230 patients were medicated in accord with multi-cancer panel data. Japanese patients with biliary tumors might derive benefit from multi-cancer genome profiling.